Changeflow GovPing Healthcare & Life Sciences NDI-1435 IMG-1 Original Notification
Routine Notice Added Final

NDI-1435 IMG-1 Original Notification

Email

Summary

FDA received an original New Dietary Ingredient notification (NDI-1435) for the substance identified as IMG-1, filed under docket FDA-2025-S-0023-0128. The notification was submitted through regulations.gov as a pre-market safety filing required under 21 CFR Part 190.6. NDI notifications initiate FDA's 75-day review period during which the agency may determine whether the ingredient poses a safety concern, without formally approving or rejecting the filing.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.

What changed

FDA received an original New Dietary Ingredient notification for the substance designated IMG-1 (NDI-1435), submitted under the pre-market notification requirement codified at 21 CFR Part 190.6. The notification was filed in docket FDA-2025-S-0023-0128 and is accessible via regulations.gov.

Dietary supplement manufacturers and ingredient suppliers should be aware that the NDI notification process requires submission of safety data at least 75 days before marketing a dietary ingredient not marketed in the United States before October 15, 1994. While FDA does not formally approve NDI notifications, the agency may issue an objection letter if it determines the ingredient is not reasonably expected to be safe, which could affect the commercial viability of IMG-1 pending outcome of the review period.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Download File

Download

CFR references

21 CFR Part 190

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2025-S-0023-0128

Who this affects

Applies to
Drug manufacturers Food manufacturers
Industry sector
3114 Food & Beverage Manufacturing
Activity scope
Regulatory filing Ingredient notification Pre-market safety review
Geographic scope
United States US

Taxonomy

Primary area
Food Safety
Operational domain
Regulatory Affairs
Topics
Consumer Protection Public Health

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!